1.A study on the use of massage by nurses to relieve cancer pain and factors affecting this usage
Tomoko Arahata ; Hiroko Komatsu
Palliative Care Research 2010;5(1):101-113
Purpose: This study investigates the situation surrounding the use of massage to relieve cancer pain by nurses in hospices and palliative care wards all over Japan and factors affecting this usage. Methods: We conducted a survey of 989 nurses with two or more years of clinical experience employed at approved palliative care wards around Japan, using a questionnaire prepared by researchers. Results: The questionnaire was answered by 606 nurses, and 95.7% of the subjects used massage in their routine nursing care. They recognized the benefits, such as comfort, reducing anxiety and so on. From a multivariate logistic model, 'a great number of years of clinical experience in cancer nursing' (OR: 2.51, 95%CI: 1.20-4.80) and 'the superior assessment ability for the use of massage' (OR: 1.18, 95%CI: 1.09-1.27) had a significant impact on the active use of massage. Conclusion: In order to use massage more effectively it is necessary to develop knowledge acquired through clinical experience and improve nurse's assessment ability. Palliat Care Res 2010; 5(1): 101-113
2.Effect of Continuous Infusion of Midazolam on Refractory Headache and/or Nausea in Patients with Intracranial Cancer Lesions
Akiko HAGIWARA ; Aya MAKINO ; Hiroko HARADA ; Koji ODA ; Sigeko MATSUYAMA ; Tomoko KOMATSU ; Yumi SATO ; Shuichi KAMIYAMA ; Erika OKAMI ; Yukiko GODA
Palliative Care Research 2024;19(1):71-76
Objective: To investigate the effectiveness and safety of continuous infusion of midazolam for the treatment of headache and/or nausea/vomiting in patients with brain tumors or cancer-associated meningitis. Methods: Patients who presented with headache and/or nausea/vomiting and underwent continuous infusion of midazolam from April 2005 to March 2021 were retrospectively analyzed. Results: Among 22 patients, 19 presented with headache and 14 with nausea/vomiting. The success rate of continuous infusion of midazolam for headache was 89% and that for nausea/vomiting was 78%. The mean number of vomiting episodes within 24 hours from the start of midazolam administration was 0.14±0.36, which was significantly lower than that from 24 hours before to the start of administration (1.43±1.60, P=0.015). Sedation was observed as an adverse event in five (23%) patients, but no patients developed respiratory depression. Conclusion: When conventional therapies are ineffective for headache and/or nausea/vomiting caused by brain tumors or cancer-associated meningitis, continuous infusion of midazolam may improve symptoms and should be considered as a treatment option.